Peptide Array Immunoprofiling for Therapeutic Target Discovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying therapeutic targets, particularly for autoimmune disorders and emerging pathogens, are not cost-effective, practical, or reliable, and lack the ability to characterize newly discovered proteins effectively, limiting their application in drug and vaccine development.
Innovation Solution
The method involves contacting a peptide array with a biological sample from an individual with an autoimmune disorder to detect antibody binding, comparing the immunosignature profile to a control sample, and identifying peptides associated with downregulated antibodies to identify therapeutic targets, utilizing a high-throughput technology that quantitates circulating antibodies and their dynamics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high-throughput technologies such as DNA, RNA, protein, antibody, and peptide microarrays are used to examine differences across drug treatments, diseases, transgenic animals, then the quantity of data acquired increases, but the complexity of interpreting the data increases and specialized algorithms need to be created, developed, and optimized
Solution Approach 1:
The patent segments the complex data interpretation process into distinct functional modules: (1) peptide array fabrication with specific patterns, (2) antibody binding detection, (3) immunosignature profile generation, (4) pattern comparison algorithms, and (5) therapeutic target identification. This segmentation allows each component to be optimized independently while working together to handle the complexity of high-throughput data interpretation.
Solution Approach 2:
The patent introduces an intermediary approach by using peptide microarrays as physical mediators between the complex biological samples and the analysis algorithms. The arrays translate complex antibody profiles into measurable binding patterns, which then can be processed by computational algorithms to identify therapeutic targets, thereby mediating between data acquisition and interpretation complexity.
2Productivity
If current high-throughput technologies are used for target identifying screening, then the productivity increases, but the reliability and practical application are limited
Solution Approach 1:
The patent changes key parameters of the screening process: using peptide arrays with specific amino acid sequences and patterns instead of generic protein arrays, implementing controlled binding conditions with specific antibodies, and establishing comparative profiles between disease and control samples. These parameter changes enhance the reliability of target identification while maintaining high throughput.
Solution Approach 2:
The patent incorporates feedback mechanisms by comparing immunosignature profiles from disease samples against control samples, using algorithmic analysis to validate identified targets, and iteratively refining the screening process. This feedback loop ensures that only reliable targets are identified, improving both productivity and reliability simultaneously.
3Measurement precision
If specialized algorithms are created, developed, and optimized for analysis, then the measurement precision improves, but the device complexity and time required increase
Solution Approach 1:
The patent applies preliminary action by pre-fabricating peptide arrays with specific patterns and pre-establishing control profiles, which allows for rapid comparison during actual screening. The algorithms are pre-optimized for specific comparison tasks, reducing real-time processing time while maintaining high measurement precision in identifying therapeutic targets.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the personalized identification of therapeutic targets by detecting changes in antibody profiles, enabling the development of specific treatments for conditions like autoimmune disorders and infections, and facilitating the discovery of novel proteins associated with diseases.
Implementation Method 1
detecting binding of at least one antibody in the first biological sample with the first peptide array to obtain a first immunosignature profile
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed are methods and devices to provide efficient methods and systems for discovering therapeutic targets, novel antigens, and for deciphering an immunosignature. The invention discloses methods for the identification of unique peptides which form an immunosignature. The invention can be applied to target identifying screening in drug discovery.